Despite pembrolizumab reimbursement in 2017 as 1L monotherapy for patients with LAM NSCLC and PD-L1 ≥50% in France (9), only 0.6% of our study population was treated with an ICI (other than nivolumab) as 1L therapy prior to index nivolumab, yet almost 60% of our cohort commenced index nivolumab in or after 2017. This evidence concerns the gene CD274 and non-small cell lung carcinoma.